Third Pole Therapeutics Receives $32M Strategic Equity Investment To Accelerate Its Tankless Inhaled Nitric Oxide (Ino) Platform

Dec 14, 2022•about 3 years ago

Amount Raised

$32 Million

WalthamHealth CareMedicalManufacturing

Description

Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.

Company Information

Company

Third Pole

Location

309 WAVERLEY OAKS ROAD

Waltham, Massachusetts, United States

About

Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team’s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies. Our first product is being designed to be a simple, convenient, economical, and lightweight device capable of generating nitric oxide from air on-demand and on-site which potentially eliminates the need for large compressed gas cylinders. We believe our novel approach of creating NO on demand has the promise to create new markets by enabling the worldwide use of inhaled NO in settings outside of acute care.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Third Pole Therapeutics Receives $32M Strategic Equity Investment To Accelerate Its Tankless Inhaled Nitric Oxide (Ino) Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information